TISIDB

Summary
Symbol	LRRC4C
Name	leucine rich repeat containing 4C
Aliases	KIAA1580; NGL-1; NGL1; netrin-G1 ligand; Leucine-rich repeat-containing protein 4C
Chromosomal Location	11p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell junction, synapse, postsynaptic cell membrane Single-pass type I membrane protein
Domain	PF07679 Immunoglobulin I-set domain PF13306 Leucine rich repeats (6 copies) PF13855 Leucine rich repeat
Function	May promote neurite outgrowth of developing thalamic neurons.

> Gene Ontology [ TOP ]
Biological Process	GO:0001933 negative regulation of protein phosphorylation GO:0006469 negative regulation of protein kinase activity GO:0007259 JAK-STAT cascade GO:0007409 axonogenesis GO:0010769 regulation of cell morphogenesis involved in differentiation GO:0010975 regulation of neuron projection development GO:0022604 regulation of cell morphogenesis GO:0033673 negative regulation of kinase activity GO:0042326 negative regulation of phosphorylation GO:0046425 regulation of JAK-STAT cascade GO:0046426 negative regulation of JAK-STAT cascade GO:0048667 cell morphogenesis involved in neuron differentiation GO:0050770 regulation of axonogenesis GO:0051348 negative regulation of transferase activity GO:0061564 axon development GO:0097696 STAT cascade GO:1902532 negative regulation of intracellular signal transduction GO:1904892 regulation of STAT cascade GO:1904893 negative regulation of STAT cascade
Molecular Function	GO:0004857 enzyme inhibitor activity GO:0004860 protein kinase inhibitor activity GO:0019207 kinase regulator activity GO:0019210 kinase inhibitor activity GO:0019887 protein kinase regulator activity
Cellular Component	GO:0045211 postsynaptic membrane GO:0097060 synaptic membrane GO:0098794 postsynapse

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04360 Axon guidance hsa04514 Cell adhesion molecules (CAMs)
Reactome	-

Summary
Symbol	LRRC4C
Name	leucine rich repeat containing 4C
Aliases	KIAA1580; NGL-1; NGL1; netrin-G1 ligand; Leucine-rich repeat-containing protein 4C
Chromosomal Location	11p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between LRRC4C and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	LRRC4C
Name	leucine rich repeat containing 4C
Aliases	KIAA1580; NGL-1; NGL1; netrin-G1 ligand; Leucine-rich repeat-containing protein 4C
Chromosomal Location	11p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of LRRC4C in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	LRRC4C
Name	leucine rich repeat containing 4C
Aliases	KIAA1580; NGL-1; NGL1; netrin-G1 ligand; Leucine-rich repeat-containing protein 4C
Chromosomal Location	11p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of LRRC4C in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.451	0.12
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.835	0.142
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.178	0.681
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-1.275	0.0327
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-1.276	0.298
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-1.289	0.288
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.065	0.931
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.507	0.683
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.926	0.436
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.048	0.944
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.673	0.444
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.67	0.00529

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of LRRC4C in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	14.3	5.9	8.4	0.576
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	25	7.1	17.9	0.405
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	4.1	7	0.339
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	5.1	6	0.373
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	14.3	11.8	2.5	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	18.2	-2.8	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	7.9	0	7.9	0.26
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	LRRC4C
Name	leucine rich repeat containing 4C
Aliases	KIAA1580; NGL-1; NGL1; netrin-G1 ligand; Leucine-rich repeat-containing protein 4C
Chromosomal Location	11p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LRRC4C. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	LRRC4C
Name	leucine rich repeat containing 4C
Aliases	KIAA1580; NGL-1; NGL1; netrin-G1 ligand; Leucine-rich repeat-containing protein 4C
Chromosomal Location	11p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LRRC4C. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LRRC4C. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	LRRC4C
Name	leucine rich repeat containing 4C
Aliases	KIAA1580; NGL-1; NGL1; netrin-G1 ligand; Leucine-rich repeat-containing protein 4C
Chromosomal Location	11p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LRRC4C. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	LRRC4C
Name	leucine rich repeat containing 4C
Aliases	KIAA1580; NGL-1; NGL1; netrin-G1 ligand; Leucine-rich repeat-containing protein 4C
Chromosomal Location	11p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of LRRC4C expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	LRRC4C
Name	leucine rich repeat containing 4C
Aliases	KIAA1580; NGL-1; NGL1; netrin-G1 ligand; Leucine-rich repeat-containing protein 4C
Chromosomal Location	11p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between LRRC4C and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	LRRC4C
Name	leucine rich repeat containing 4C
Aliases	KIAA1580; NGL-1; NGL1; netrin-G1 ligand; Leucine-rich repeat-containing protein 4C
Chromosomal Location	11p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting LRRC4C collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse LRRC4C